What's hot? Small-cap and biotechnology, for two things. That's why
two major exchange traded fund (
) providers have funds either launching or in the works to cover
both of these popular asset classes.
is gearing up to launch a whole suite of small-cap single-country
ETFs. The firm will start a small-cap South Korean ETF today and
follow up with others later. A small-cap Taiwan ETF should launch
in two weeks, followed by ETFs tracking Hong Kong, Singapore,
Canada and Australia. [
Specialty Emerging Market ETFs On a Roll.
The small-cap family of ETFs will help investors track specialty
areas of emerging and developed nations overseas. They will
specifically target small-caps, as they have outperformed the
larger-cap counterparts. [
Why Small-Caps Are Outperforming.
Biotechnology is not only a bright spot in the U.S. economy, it
is an active spot that is waiting for Congress's next move.
, the world's biggest provider of inverse and leveraged ETFs,
rolled out a pair of leveraged and inverse ETFs targeting the
says Oliver Ludwig for Index Universe
Feeling Contrary? Here's an ETF for You.
The latest ETFs are:
Ultra Nasdaq Biotechnology (
Seeks to double the daily returns of the Nasdaq Biotechnology
UltraShort Nasdaq Biotechnology (NASDAQ:
Designed to deliver twice the inverse of the index's daily
Please remember that leveraged and inverse funds are designed
for more hands-on, risk-tolerant investors, as long-term returns
can vary widely from daily objectives. These are not buy-and-hold
tools and should be monitored daily. [
6 Top ETFs of the First Quarter.
For more stories about new ETFs, visit our
new ETFs category